399 related articles for article (PubMed ID: 37447164)
41. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
42. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
43. Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease.
St-Jules DE; Watters CA; Brunt EM; Wilkens LR; Novotny R; Belt P; Lavine JE;
J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):627-33. PubMed ID: 24177784
[TBL] [Abstract][Full Text] [Related]
44. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease.
Eslamparast T; Tandon P; Raman M
Nutrients; 2017 Jul; 9(8):. PubMed ID: 28933748
[TBL] [Abstract][Full Text] [Related]
45. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease.
Panera N; Barbaro B; Della Corte C; Mosca A; Nobili V; Alisi A
Nutr Res; 2018 Oct; 58():1-16. PubMed ID: 30340810
[TBL] [Abstract][Full Text] [Related]
46. Nutritional recommendations for patients with non-alcoholic fatty liver diseases.
Assy N
World J Gastroenterol; 2011 Aug; 17(29):3375-6. PubMed ID: 21876629
[TBL] [Abstract][Full Text] [Related]
47. Chia (Salvia hispanica)-supplemented diet ameliorates non-alcoholic fatty liver disease and its metabolic abnormalities in humans.
Medina-Urrutia A; Lopez-Uribe AR; El Hafidi M; González-Salazar MDC; Posadas-Sánchez R; Jorge-Galarza E; Del Valle-Mondragón L; Juárez-Rojas JG
Lipids Health Dis; 2020 May; 19(1):96. PubMed ID: 32430018
[TBL] [Abstract][Full Text] [Related]
48. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
49. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
Paglialunga S; Dehn CA
Lipids Health Dis; 2016 Sep; 15(1):159. PubMed ID: 27640119
[TBL] [Abstract][Full Text] [Related]
50. Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review.
Katsagoni CN; Papachristou E; Sidossis A; Sidossis L
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32961669
[TBL] [Abstract][Full Text] [Related]
51. Liver Fat Scores Moderately Reflect Interventional Changes in Liver Fat Content by a Low-Fat Diet but Not by a Low-Carb Diet.
Kabisch S; Bäther S; Dambeck U; Kemper M; Gerbracht C; Honsek C; Sachno A; Pfeiffer AFH
Nutrients; 2018 Jan; 10(2):. PubMed ID: 29385034
[TBL] [Abstract][Full Text] [Related]
52. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
53. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
54. Experimental models of non-alcoholic fatty liver disease in rats.
Kucera O; Cervinkova Z
World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
[TBL] [Abstract][Full Text] [Related]
55. Survey of Dietary Habits and Physical Activity in Japanese Patients with Non-Obese Non-Alcoholic Fatty Liver Disease.
Yabe Y; Chihara K; Oshida N; Kamimaki T; Hasegawa N; Isobe T; Shoda J
Nutrients; 2023 Jun; 15(12):. PubMed ID: 37375668
[TBL] [Abstract][Full Text] [Related]
56. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
57. Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studies.
Bayram HM; Majoo FM; Ozturkcan A
Clin Nutr ESPEN; 2021 Aug; 44():1-14. PubMed ID: 34330452
[TBL] [Abstract][Full Text] [Related]
58. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
59. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
60. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
